clinical trial · NCT07324629
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 30
Thymic CarcinomaSacituzumab tirumotecan
brief summary
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are: * How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT? Participants will: * Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.
started
Jan 1, 2026
primary completion
Apr 1, 2028
completion
Oct 1, 2028
last updated
Jan 9, 2026
official title
A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol